Aрpellant Everette Bryan Love was stopped on 1-85 in Gwinnett County for speeding at 11:30 p.m. on May 31, 1996. After approaching appellant’s stopped vehicle, the officer arrested appellant for driving under the influence based on the odor of marijuana emanating frоm appellant’s car. Samples of appellant’s blood and urine were taken and sent to the Crime Lab' for analysis which revealed the presence of marijuana metabolites in appellant’s blood and urine. Appellant was charged with driving under the influence of drugs to the extent he was a less safe driver (OCGA § 40-6-391 (a) (2)), and driving with marijuana in his blood or urine. OCGA § 40-6-391 (a) (6).
1
The trial court denied appellant’s motion to quash which was based, in part, on the assertion that OCGA § 40-6-391 (a) (6) was unconstitutional. Appellant was convicted of driving with unlawful drugs present in his blood or urine, but the jury was unable tо reach
a verdict on the charge that appellant was driving under the influence of drugs to the extent it made him a less safe driver. On appeal, appellant renews his attacks on the constitutionality of the statute and sees error in the trial court’s denial of his motion to
1. Appellant contends the trial court erroneously failed to suppress the results of the tests conducted on his blood and urine because the testing methods had not been approved under the Administrative Procedure Act (APA), OCGA § 50-13-1 et seq., and therefore were not “performed according to methods approved by the Division of Forensic Sciences of the Georgia Bureau of Investigation,” as required by OCGA § 40-6-392 (a) (1) (A). During its 1997 legislative session, the Georgia General Assembly passed the Forensic Sciences Act, which made the APA inapplicable to the methods of evidence-testing adopted by the GBI’s Division of Forensic Sciences. OCGA § 35-3-155. Appellant asserts that the 1997 legislation cannot be applied to his 1996 test results, and asserts that we should overrule the appellate holding in
Helmeci v. State,
While OCGA § 35-3-155 was passed after the commission of the offense for which appellant was tried, it did not inflict a greater punishment than was permitted by the law in effect at the time of the offense; it did not make criminal an act which was innocent when done; it did not change the quality or degree of appellant’s offense; it did not require less or different evidence than required at the time of the offense; and it did not deprive appellant of any substantial right or immunity he possessed at the time of thе offense. See
Todd v. State,
2. Appellant contends that OCGA § 40-6-391 (a) (6) violates the Equal Protection Clause of both the U. S. and Georgia Constitutions because the statute singles out for punishment unimpaired drivers with low levels of marijuana metabolites in their body fluids, despite the fact that these drivers pose no threat to traffic safety, the purpose of the DUI statute. Appellant contends that there is no rational basis for treating unimрaired drivers with marijuana metabolites differently from other unimpaired drivers.
A statute attacked as unconstitutional is presumed by the judiciary to be constitutional
(State v. Brannan,
Before delving into whether there exists the rational relationship between the statute at issue and a legitimate state interest, we must first note that OCGA § 40-6-391 (a) (6) does not operate to classify a driver
Two experts, a forensic toxicologist from the Georgia Bureau of Investigation’s Division of Forensic Sciences and a toxicologist/professor at Mercer University’s School of Pharmacy, testified at a pre trial hearing, and the GBI expert testified at trial. 4 From the experts’ testimony, we learn the following general information: metabolites of marijuana can be found in the blood of one who smoked marijuana for a couple of days after the marijuana usage, and are detectable in the urine for two weeks to a month аfter usage. Marijuana smoke inhaled by one not smoking marijuana (“second-hand smoke”) can result in detectable amounts of marijuana metabolites in the inhaler’s blood and urine if the inhalation occurred in a smoke-filled, small, crowded space. The tests performed by the GBI on blood and urine specimens — Cloned Enzyme Donor Eminase (CEDIA) and Fluorescence Polarization Eminase (FPIA) — result in a “positive” reading for the presence of marijuana metabolites in the body fluid tested if the metabolites’ content is at least 100 nanograms per milliliter in urine-testing, and 25 nanograms per milliliter in blood-testing. 5 The GBI’s Division of Forensic Sciences set these minimum levels in order to exclude the possibility of a positive result from passive inhalation of second-hand marijuana smoke, or from marijuana usage which occurred several weeks before testing. Aсcording to the GBI expert, a finding of the minimum level for urine-testing indicates, for most people, marijuana use within the one-half to two days preceding the time the urine specimen was provided. The blood specimen of an infrequent marijuana user (one time per week) will cоntain the minimum level for a day, and a positive result on both urine and blood specimens indicates recent marijuana use.
Both experts testified that human beings vary in their sensitivity to marijuana. The Mercer professor testified that the “period of intoxication” varies from person to person and the effects of the drug gradually decline over a period of time, with the effects being gone in 24 hours in almost every case. The expert was unable to make a general statement about how long the drug would affect a specific person’s driving ability, but the residual effects on an inexperienced marijuana user could affect driving ability. The GBI expert testified that the loss of manual dexterity which results from marijuana usage can last up to 24 hours.
Based on the experts’ testimony and the GBI’s minimum evidentiary standard, we conclude that a statute which makes it unlawful to drive while marijuana residue is circulating in the driver’s body fluids bears a rational relationship to a legitimate state purpose — protection of the public. Through the enactment of a per se prohibi
tion against driving after using marijuana, the General Assembly has acted to shield the public from the potential dangers presented by persons who drive while experiencing the effects of
3. Appellant next contends that § 40-6-391 (a) (6) violates equal protection “by arbitrarily changing the burden of proof of guilt for ‘legal’ marijuana users,” pointing out that a person legally entitled to use marijuana who is driving with marijuana metabolites in his body fluids may only be convicted of violating § 40-6-391 (a) (6) if “such person is rendered incapable of driving safely as a result of using [the] drug. . . .” OCGA § 40-6-391 (b). 6 Thus, the statute allows a person with metabolites of legally-used marijuana in his body fluids to be convicted of driving with marijuana in his system only if it is established that he was “rendered incapable of driving safely” while a person with metabolites of illegally-used marijuana can be found guilty of driving with marijuana in his system without evidence of impairment. Inasmuch as the expert testimony given in this casе stated that the pharmacological effects of legally-used marijuana are no different from the effect of illegally-used marijuana, the statute’s disparate treatment of users of legal and illegal marijuana is predicated on the purpose for which the marijuana is used — legal marijuana users are not subject to prosecution for the per se prohibition, while illegal users of marijuana are. Thus, those whose marijuana use is legally sanctioned cannot be convicted merely for having metabolites of marijuana in their body fluids, while those whose marijuana use is not legally sanctioned can be.
Under the rational basis test, a legislative classification does not deny equal protection if the classification bears a direct relation to the purpose of the legislation.
City of Atlanta v. Watson,
supra,
4. In light of our holding in Division 3, we need not address appellant’s contention that OCGA § 40-6-391 (a) (6) violates due process of law.
Judgment reversed.
Notes
OCGA § 40-6-391 (a) (6) states that “[a] person shаll not drive or be in actual physical control of any motor vehicle while ... there is any amount of marijuana or a controlled substance . . . present in the person’s blood or urine, or both, including the metabolites and derivatives of each or both . . .,” subject to the provisions of subsection (b) of OCGA § 40-6-391. Subsection (b) provides that a person legally entitled to use a drug is not in violation of the Code section “unless such person is rendered incapable of driving safely as a result of using a drug other than alcohol which such person is legally entitled to use.” Subsection (а) (6) was formerly subsection (a) (5). In a 1996 amendment to OCGA § 40-6-391, subsection (a) (4) was added, and subsection (a) (5) was redesignated (a) (6). Ga. L. 1996, p. 1413, § 1.
Appellant also contends the Forensic Sciences Act authorizes an agency of the executive branch of government to make law and thereby violates the principle of separation of powers found in Art. I, Sec. II, Par. Ill of the Georgia Constitution. Since no such constitutional attack was raised and ruled upon in the trial court, we decline to address the issue.
Bohannon v. State,
Impairment becomes an issue when the defendant asserts that the marijuana metabolites in his body fluids are the result of using medically-prescribed marijuana. See OCGA § 40-6-391 (b).
We echo the trial court’s expression of appreciation to the parties for providing such articulate and understandable experts.
Each of the two tests was рerformed on appellant’s blood sample and his urine specimen. All four test results were positive for marijuana metabolites. Based on the findings, the GBI expert opined that appellant had smoked marijuana sometime the day of his arrest.
Several foreign countries, mоst notably the Netherlands, permit marijuana use. In Georgia, OCGA § 43-34-121 (d) authorizes qualified physicians to provide marijuana “to seriously ill persons suffering from the severe side effects of chemotherapy or radiation treatment and to persons suffering from glaucoma who are not responding to conventional treatment,” and subsection (e) expresses the legislative intent to facilitate clinical trials and research into therapeutic applications of marijuana for glaucoma and the side effects of chemotherapeutic agents and radiation.
